Aurion Biotech Expands Its Leadership Team
Retrieved on:
Wednesday, November 30, 2022
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Optical, Science, Gilead Sciences, Takeda Pharmaceutical Company, Liberty University, Human services, Union, University, Multimedia, Purdue University, Seagen, Abbott Laboratories, BLA, Patient, BS, Regulatory affairs, Endothelial dysfunction, Biotechnology, Petrichor, American University, NDA, AMD, Alcon, Political science, Sherita Ceasar, Clinical trial, Pharmaceutical industry, Psychology, Biology
View the full release here: https://www.businesswire.com/news/home/20221130005132/en/
Key Points:
- View the full release here: https://www.businesswire.com/news/home/20221130005132/en/
Im delighted to welcome Sherita and Sterling to Aurion Biotech, said Greg Kunst, Aurion Biotech chief executive officer. - Before joining Aurion Biotech, Mr. Chung held regulatory leadership roles at Neoleukin Therapeutics, Molecular Templates, Immatics US, Seattle Genetics, Gilead Sciences, Astellas Pharmaceuticals, Takeda Pharmaceuticals, and Abbott Laboratories.
- With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies.
- Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech.